AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Close
Create a link to this page
Copy and paste this link tag into your Web page or blog:
<a href="http://www.accessmylibrary.com/coms2/summary_0286-22849918_ITM" title="Facts and information about JAPAN'S SOSEI, U.S. BIOTECH FIRM TO DEVELOP ALLERGY MEDICATION.">JAPAN'S SOSEI, U.S. BIOTECH FIRM TO DEVELOP ALLERGY MEDICATION.</a>
Close
Set up an RSS feed that alerts you when new articles from AsiaPulse News are available.
Frequently asked questions about RSS feeds
JAPAN'S SOSEI, U.S. BIOTECH FIRM TO DEVELOP ALLERGY MEDICATION.
TOKYO, April 1 Asia Pulse - Sosei Co. plans to jointly develop an allergy medicine with U.S. biotechnology firm Abgenix Inc.
Sosei obtained the rights to develop antibodies that will fight a protein called CRTH2, a novel receptor related to allergies, from BML Inc., a major clinical testing company.
Sosei and Abgenix plan to develop an antibody that inhibits the functions of allergy-causing proteins. Abgenix plans to devise such an ...
Related articles from newspapers, magazines, journals, and more
For more facts and information, see all results
- KineMed Announces Partnership with Sosei Co. Ltd. for Repurposing Clinically...
- Press release article from: PR Newswire April 13, 2005 700+ words
...compound evaluation agreement with Sosei Co. Ltd. (4565, Tokyo Stock...provided by the library of Sosei's Drug Reprofiling Platform...through Phase I or Phase II clinical testing and have favorable safety profiles...President and CEO of KineMed. "Sosei has provided an ample number...
- Sosei Initiates Phase I Clinical Trial of Oral SOU-001.
- Press release article from: PR Newswire June 15, 2004 700+ words
...and LONDON, June 15 /PRNewswire/ -- Sosei Co. Ltd., a leading Japanese biopharmaceutical...is the first successful demonstration of Sosei's DRP(R) (Drug Reprofiling Platform...by a Japanese pharmaceutical company. Sosei's DRP(R), in collaboration with a...
- Sosei's SOU-001 Project Moves to Phase II Clinical Study.
- Press release article from: PR Newswire June 20, 2005 700+ words
...June 20 /PRNewswire-FirstCall/ -- Sosei Co. Ltd., a leading Japanese biopharmaceutical...is the first successful demonstration of Sosei's DRP(R) (Drug Reprofiling Platform...by a Japanese pharmaceutical company. Sosei's DRP(R), in collaboration with a...
- Sosei Announces Results of AD 452 Phase IIb Clinical Trial.
- Press release article from: PR Newswire November 21, 2006 700+ words
...Japan, November 21 /PRNewswire-FirstCall/ -- Sosei Group Corporation ("Sosei"; TSE Mothers Index: 4565), the biopharmaceutical...clinical trial. As a consequence of these results Sosei has decided to discontinue with the development of...
- Sosei Announces Initiation of Phase I Trial for NorLevo(R).
- Press release article from: PR Newswire November 17, 2006 700+ words
TOKYO, Nov. 16 /PRNewswire-FirstCall/ -- Sosei Group Corporation ("Sosei"; TSE Mothers Index: 4565), the biopharmaceutical...contraceptive pill (ECP) SOH-075 (NorLevo(R)). Sosei acquired the exclusive distribution rights to the...
- Sosei Announces Reorganisation of its Corporate Structure Under Holding Company.
- Press release article from: PR Newswire May 15, 2006 700+ words
...May 15 /PRNewswire-FirstCall/ -- Sosei Co. Ltd. (TSE Mothers Index: 4565) announced today that the Sosei Group will reorganise its company structure...2006. 1. Objectives of transformation Sosei is establishing itself as a global biopharmaceutical...
- Sosei to Acquire Arakis for GBP106.5 Million.
- Press release article from: PR Newswire July 19, 2005 700+ words
...and TOKYO, July 19 /PRNewswire-FirstCall/ -- Sosei Co. Ltd ("Sosei" - 4565, Tokyo Stock Exchange MOTHERS index), a...issued and to be issued share capital of Arakis by Sosei for GBP106.5 million ($187.4 million). The...
- Sosei Announces New Fundraising.
- Press release article from: PR Newswire January 5, 2007 700+ words
...Japan, January 5 /PRNewswire-FirstCall/ -- Sosei Group Corporation ("Sosei", TSE Mothers Index:4565) a biopharmaceutical...initial exercise price and the exercise of all SARs Sosei would raise approximately Yen 3.9bn. - The exercise...
Source: HighBeam Research, JAPAN'S SOSEI, U.S. BIOTECH FIRM TO DEVELOP ALLERGY MEDICATION.